Phase I/II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rapamycin resistant T-cell therapy (Primary) ; Carboplatin; Paclitaxel
Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Carcinoma; Gastric cancer; Head and neck cancer; Laryngeal cancer; Male breast cancer; Malignant melanoma; Mouth neoplasm; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Sponsors Rapa Therapeutics

27 Mar 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
27 Mar 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Jan 2024.
07 Dec 2021 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com